1. Home
  2. AGL vs IMMP Comparison

AGL vs IMMP Comparison

Compare AGL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo agilon health inc.

AGL

agilon health inc.

HOLD

Current Price

$22.68

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.31

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGL
IMMP
Founded
2016
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
58.2M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
AGL
IMMP
Price
$22.68
$0.31
Analyst Decision
Hold
Hold
Analyst Count
13
3
Target Price
$64.25
$5.50
AVG Volume (30 Days)
2.4M
1.1M
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,932,576,000.00
N/A
Revenue This Year
N/A
$417.85
Revenue Next Year
$4.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.29
52 Week High
$21.91
$3.53

Technical Indicators

Market Signals
Indicator
AGL
IMMP
Relative Strength Index (RSI) 94.44 14.38
Support Level $0.63 N/A
Resistance Level N/A $0.39
Average True Range (ATR) 1.81 0.02
MACD 1.73 0.08
Stochastic Oscillator 95.43 21.27

Price Performance

Historical Comparison
AGL
IMMP

About AGL agilon health inc.

Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: